A 43-year-old man with antisynthetase syndrome was seen in our pulmonary clinic for worsening dyspnea. He was recently diagnosed with antisynthetase syndrome because he had nonspecific interstitial pneumonitis on a surgical lung biopsy and ... CHEST, 4 weeks ago
29-Year-Old Man Presenting With Progressive Dyspnea, Oculocutaneous Albinism, and Epistaxis - CHEST, 4 weeks ago
A 52-Year-Old Man With Palpitations and a Solitary Pulmonary Nodule - CHEST, 4 weeks ago
JAMA. 2015;313(21):2174-2175. doi:10.1001/jama.2015.2713. Text Size: A A A Extract A 36-year-old woman reporting 1 month of dyspnea presents with weight loss, tongue and hand tremors, and tachycardia. What would you do next? Figures in this ...Journal of the American Medical Association, 4 weeks ago
Date: 02 Jul 2015 Rent the article at a discount Rent now * Final gross prices may vary according to local VAT. Get Access Zusammenfassung Dyspnoe bezeichnet die subjektive Wahrnehmung einer als unangenehm ...DerInternist, 15 hours ago Dyspnoe bei Linksherzerkrankungen DerInternist, 1 day ago Design and Rationale of TROCADERO: a TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr American Heart Journal, 5 days ago Dyspnoe DerInternist, 2 weeks ago
A 78-year-old female patient arrived at the ER with dyspnea, dizziness, and inter-scapular pain. Her past medical history was remarkable for coarctation of the aorta and mechanical aortic valve replacement surgery 12 years prior. The patient was ...CTSNet, 4 weeks ago
Alexion Garners CHMP Positive Opinions for Strensiq (asfotase alfa) and Kanuma (sebelipase alfa) in the European Union
Alexion Pharmaceuticals reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending marketing authorization of Strensiq (asfotase alfa) and Kanuma ...Individual.com, 6 hours ago Alexion Receives CHMP Positive Opinions for Strensiq (asfotase alfa) and Kanuma (sebelipase alfa) in the European Union Stockwatch, 5 days ago Alexion (ALXN) Receives CHMP Positive Opinions For Strensiq (Asfotase Alfa) And Kanuma (Sebelipase Alfa) In The European Union 6/26/2015 ClinicSpace, 4 days ago Alexion Receives Positive Opinions For Strensiq (Asfotase Alfa) And Kanuma (Sebelipase Alfa) In The European Union BioSpace, 4 days ago
CHICAGO—The anti-CD38 antibody daratumumab is effective as a stand-alone therapy for heavily pretreated multiple myeloma patients, according to the results of an open-label, international, multicenter Phase II trial reported here the American ...Oncology Times, 4 hours ago
0 Flares 0 Flares × FROM JOURNAL OF CLINICAL ONCOLOGY Thirty-minute infusions of ipilimumab appear to be as safe as standard 90-minute infusions for patients with metastatic melanoma and other solid tumors, with an acceptably low ...PM 360, 11 hours ago
New Tuberculosis Findings Has Been Reported by Researchers at Chonnam National University Hospital (Risk factors for death during pulmonary...
New Tuberculosis Findings Has Been Reported by Researchers at Chonnam National University Hospital (Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study) By a News Reporter-Staff News ...Pharmacy Choice, 1 day ago Researchers from University of Rochester Report Recent Findings in Lung Cancer (Opioid Use in the Last Year of Life Among Medicare Beneficiaries With... Pharmacy Choice, 3 weeks ago
By Ebrima Manjang, a 4-year-old boy and resident of Kanifing is in urgent need of help to undergo cardiac surgery overseas, a medical report issued by the Serrekunda General Hospital and signed by Dr Mbemba Drammeh has strongly recommended. Ebrima ...AllAfrica.com, 1 day ago Four-Year-Old Boy Needs Urgent Overseas Treatment Individual.com, 1 day ago
Merck & Co. Announces Phase III Study Of Single-Dose EMEND?? (Fosaprepitant Dimeglumine) For Injection Regimen Met Primary Endpoint In Prevention Of Chemotherapy-Induced Nausea And Vomiting In Patients Receiving Moderately Emetogenic Chemotherapy
KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND ® (fosaprepitant ...BioSpace, 1 day ago Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint Benzinga.com, 2 days ago MERCK : Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 4 Traders, 2 days ago European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Pa Industrial Info Financials, 1 week ago
on your WebpageAdd Widget >Get your members hooked!